Prostate Cancer

Latest News

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.
Data Show Short-Course Radiotherapy Increase in Prostate Cancer

November 30th 2023

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Olaparib Combo Does Not Yield Significant OS Benefit Vs Placebo in mCRPC | Image Credit: © Dr_Microbe - stock.adobe.com.
Olaparib Combo Does Not Yield Significant OS Benefit Vs Placebo in mCRPC

November 12th 2023

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.
Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer

November 7th 2023

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.
Pembrolizumab/177Lu-PSMA-617 May Be a New Treatment for Patients with mCRPC

November 1st 2023

With the announcement that the supply of 177Lu vipivotide tetraxetan is now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer.
FDA Classifies 177Lu Vipivotide Tetraxetan Drug Shortage as Resolved

October 31st 2023

Latest CME Events & Activities

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News